A Phase 4 interventional study of Lubricant Eye Drops (Optive™) and Lubricating Eye Drops (blink® Tears) in Dry Eye Syndromes, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-31.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Lubricant Eye Drops in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. Lubricant Eye Drops · Dry Eye Syndromes.
Among the 10 studies testing Lubricant Eye Drops in Dry Eye Syndromes, this one is the 3rd largest by enrollment, is the only one that started in 2008, is one of 5 in phase 4, and was the 2nd registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →2 of the 10 studies testing Lubricant Eye Drops in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:
Zhongshan Ophthalmic Center, Sun Yat-sen University
Ages 18–65
BRIM Biotechnology Inc. · Sites in Taiwan
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 39 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
48 studies in Dry Eye Syndromes by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 47 finished, 40 (85%) have results posted.
Among the 48 studies in Dry Eye Syndromes by AbbVie, this one is the 26th largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2008, is one of 9 in phase 4, and was the 6th registered.
AbbVie’s Dry Eye Syndromes studies by the year they started, since 2001.
1 of the studies testing Lubricant Eye Drops in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07078955BRIM Biotechnology Inc.A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing Lubricant Eye Drops in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 48 in Dry Eye Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Efficacy and acceptability of two new artificial tears following two weeks of treatment in patients with dry eye. Patients will be randomized to 1 of 2 treatments for 7 days then crossover to the alternate treatment for 7 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Carboxymethylcellulose and Glycerin
Drug: Lubricant Eye Drops (Optive™)
Polyethylene glycol 400
Drug: Lubricating Eye Drops (blink® Tears)
1 drop in both eyes as needed for 7 days'
Also known as: Optive™
1 drop in both eyes as needed for 7 days
Also known as: blink® Tears
Mean Frequency of Eye Drop Use Over 1 Week
Mean frequency of eye drop use per day per patient during the cross-over period over 1 week. Eye drop use was captured on a daily tear diary that the patients completed. The greater the frequency of use, the more eye drops were required to manage the patient's dry eye symptoms.
Time frame: 1 week
Change From Baseline in Dry Eye Disease Comfort Assessment Score on Day 16
Mean change from baseline in Dry Eye Disease Comfort Assessment Score at Day 16. The Dry Eye Disease Comfort Assessment consists of one question asking the patient to rate their current overall discomfort from their dry eye symptoms on a scale of 0 to 10 (0 equals No Discomfort; 10 equals Intolerable). The greater the negative number change from baseline, the greater the improvement in comfort.
Time frame: Baseline, Day 16
Percentage of Positive Patient Responses to Subject Acceptability Questionnaire on Day 16
Percentage of patients who responded "Strongly Agree" and "Agree" to Subject Acceptability Questionnaire Question 1: Overall Liked. The Subject Acceptability Questionnaire consists of 11 multiple choice questions assessing how the patients feel about the eye drops received. The 5 possible responses to the questionnaire are "Strongly Agree", "Agree", "Neither Agree or Disagree", "Disagree" and "Strongly Disagree".
Time frame: Day 16
Number of Patients With Positive Responses to Subject Preference Questionnaire on Day 16
Number of patients who marked that either Week 1 study product was more soothing or Week 2 study product was more soothing to the Overall Comfort Preference Questionnaire on Day 16 of the cross-over period. The Subject Preference Questionnaire consists of 4 questions related to comfort, soothing, blurring and purchase preference comparing treatments received during Week 1 versus Week 2.
Time frame: Day 16
| Milestone | All Patients |
|---|---|
| Started | 51 |
| Completed | 50 |
| Not completed | 1 |
Mean frequency of eye drop use per day per patient during the cross-over period over 1 week. Eye drop use was captured on a daily tear diary that the patients completed. The greater the frequency of use, the more eye drops were required to manage the patient's dry eye symptoms.
| Use per day | Lubricant Eye Drops (Optive™) | Lubricant Eye Drops (Blink® Tears) |
|---|---|---|
| Mean Frequency of Eye Drop Use Over 1 Week | 1.76 ± 0.89921 | 1.66 ± 0.94459 |
Mean change from baseline in Dry Eye Disease Comfort Assessment Score at Day 16. The Dry Eye Disease Comfort Assessment consists of one question asking the patient to rate their current overall discomfort from their dry eye symptoms on a scale of 0 to 10 (0 equals No Discomfort; 10 equals Intolerable). The greater the negative number change from baseline, the greater the improvement in comfort.
| Scores on a scale | Lubricant Eye Drops (Optive™) | Lubricant Eye Drops (Blink® Tears) |
|---|---|---|
| Baseline | 4.65 ± 1.843 | 4.62 ± 1.839 |
| Day 16 | -1.41 ± 2.010 | -1.47 ± 1.905 |
Percentage of patients who responded "Strongly Agree" and "Agree" to Subject Acceptability Questionnaire Question 1: Overall Liked. The Subject Acceptability Questionnaire consists of 11 multiple choice questions assessing how the patients feel about the eye drops received. The 5 possible responses to the questionnaire are "Strongly Agree", "Agree", "Neither Agree or Disagree", "Disagree" and "Strongly Disagree".
| Percentage of Patients | Lubricant Eye Drops (Optive™) | Lubricant Eye Drops (Blink® Tears) |
|---|---|---|
| Percentage of Positive Patient Responses to Subject Acceptability Questionnaire on Day 16 | 86 | 78 |
Number of patients who marked that either Week 1 study product was more soothing or Week 2 study product was more soothing to the Overall Comfort Preference Questionnaire on Day 16 of the cross-over period. The Subject Preference Questionnaire consists of 4 questions related to comfort, soothing, blurring and purchase preference comparing treatments received during Week 1 versus Week 2.
| Number of patients | Lubricant Eye Drops (Optive™) | Lubricant Eye Drops (Blink® Tears) |
|---|---|---|
| Number of Patients With Positive Responses to Subject Preference Questionnaire on Day 16 | 16 | 22 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Patients | — | 0/51 (0%) | 0/51 (0%) |
| Age, Customized(participants) | All Patients |
|---|---|
| <=40 years | 22 |
| Between 40 and 65 years | 24 |
| >=65 years | 5 |
| Sex: Female, Male(Participants) | All Patients |
|---|---|
| Female | 37 |
| Male | 14 |
The record gives a start of Sep 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lubricant Eye Drops